CD19 and acute lymphoblastic leukemia: The OS estimate observed in our study (without any difference between ALL, either of T or B lineage, AML patients), in line with our recently published cohort (13), is higher than that reported in other pediatric trials of CD34 selected (57, 58) or CD3/CD19-depleted haploidentical HSCT (48), suggesting a favorable impact of TcRγδ T-cells on outcome.